0000899243-20-024183.txt : 20200903
0000899243-20-024183.hdr.sgml : 20200903
20200903183436
ACCESSION NUMBER: 0000899243-20-024183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200901
FILED AS OF DATE: 20200903
DATE AS OF CHANGE: 20200903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CATHERS BRIAN EDWIN
CENTRAL INDEX KEY: 0001769127
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 201160272
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001769127
CATHERS BRIAN EDWIN
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific Officer
Common Stock
2020-09-01
4
M
0
3750
A
8994
D
Common Stock
2020-09-01
4
F
0
1551
60.45
D
7443
D
Restricted Stock Units
2020-09-01
4
M
0
3750
0.00
D
Common Stock
3750
18750
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,750 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the shares on March 1, 2020 and thereafter 1/6th of the remaining underlying shares shall vest in semi-annual installments over 3 years from March 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/ Tricia Suvari, as Attorney-in-Fact
2020-09-03